The pharmacology of sleep is a domain where clinical convention and longevity-psychiatry principle diverge substantially. The dominant prescribing patterns — chronic benzodiazepines, chronic Z-drugs, low-dose quetiapine off-label for insomnia, OTC anticholinergic sleep aids — are inconsistent with what the field knows about cognitive cost. The clinical task is to prescribe sleep medication with the same discipline that prescribing any chronic medication requires: which agent, at what dose, for what duration, with what monitoring, and with what plan for eventual discontinuation when possible.
The first principle: not all sedation is restorative sleep. A patient knocked unconscious by alcohol, diphenhydramine, or a high-dose benzodiazepine is not getting the same quality of sleep as a patient who falls asleep through normal physiology. The architecture is different. The glymphatic clearance is different. The memory consolidation is different. The clinical implication is that a medication that reliably produces unconsciousness is not necessarily a medication that produces brain-protective sleep.
Benzodiazepines in detail: short-term use for acute situational insomnia, severe anxiety attacks, or alcohol withdrawal is appropriate and time-limited. Chronic use as a sleep aid is associated with cognitive decline in observational studies, tolerance that erodes efficacy, dependency that makes discontinuation difficult, increased fall risk in older adults, and (in some populations) elevated dementia risk. The clinical reality is that many patients on chronic benzodiazepines started them years ago for reasons that no longer apply, and the continuation is inertia plus rebound concerns rather than clinical justification. Slow tapers (months, not weeks) succeed where rapid tapers fail.
Z-drugs (zolpidem, eszopiclone, zaleplon) are marketed as different from benzodiazepines but operate on the same GABA-A receptor system with somewhat different subunit selectivity. The clinical advantages are modest. The cognitive concerns are similar. The same principle applies: short-term use is reasonable; chronic use carries cognitive cost that accumulates and is often unrecognized. The patient on zolpidem for eight years should be reevaluated.
Trazodone at 25–100mg qhs is the workhorse of cognitively-friendlier sleep pharmacology. Mechanism is primarily 5-HT2A antagonism and H1 antagonism at sleep doses, with minimal anticholinergic burden, no respiratory depression, no dependency, and modest cost. The clinical role is wide — first-line agent for many adult patients, particularly with comorbid depression. Side effects are usually manageable: orthostasis (especially elderly), morning hangover at higher doses, rare priapism in male patients.
Low-dose doxepin (3–6mg) is selectively H1-antagonist at these doses, with minimal anticholinergic burden — a clinically important distinction from doxepin at antidepressant doses (75–300mg) where anticholinergic effects are substantial. The low-dose preparation is FDA-approved for sleep maintenance specifically. It is particularly useful in elderly patients where anticholinergic burden is a major consideration. Brand Silenor is expensive; compounded generic at the same dose is comparable.
The dual orexin receptor antagonists (DORAs) — suvorexant, lemborexant, daridorexant — block the wake-promoting orexin/hypocretin system rather than potentiating sleep-promoting GABA. The clinical advantages are real: less fall risk in older adults, less cognitive impairment, less dependency, less rebound on discontinuation, less impact on sleep architecture. The disadvantages are mostly economic — cost is substantial, insurance coverage often requires step therapy through cheaper agents first, and access can be a real barrier. For patients who can access them, DORAs are the most cognitively-friendly hypnotic class currently available.
Melatonin and ramelteon work on melatonin receptors. Low-dose melatonin (0.3–1mg, not the OTC 3–10mg) is appropriate for circadian-rhythm interventions and for older adults whose endogenous secretion has declined. Ramelteon is the FDA-approved melatonin agonist; mechanism is similar but the receptor selectivity differs. Both are very safe with minimal cognitive impact; efficacy is modest and works best for sleep-onset rather than sleep-maintenance insomnia.